(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Mobility exercises are an important part of fitness as we age. Here are some tips - 2Benin coup thwarted by loyalist troops, president tells nation
- 3Figuring out Significant Regulations and Guidelines for Organizations
- 4Exhaustive Experiences into Prudent Senior Living in the UK
- 5Nexi expands alliance with PayPal
- Zelensky names spy chief to head presidential office after corruption row
- The Response to Self-improvement: Embracing a Development Outlook
- The Green Transformation: 5 Feasible Living Practices
- Step by step instructions to Keep up with Great Hand Cleanliness Before Handshakes
- Former IRGC child executioner tells ‘Post’ how he became devout Christian dissident
- New Jordan security fence could be done in early 2028
- FOX8 Meteorologist Charles Ewing makes his 2025-26 winter weather predictions!
- 'Seditious behavior': Trump accuses Democrats who made video reminding the military not to follow illegal orders of a crime — but is it?
- AbbVie plans to build out its presence in obesity market
